<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597256</url>
  </required_header>
  <id_info>
    <org_study_id>43CH1627</org_study_id>
    <nct_id>NCT03597256</nct_id>
  </id_info>
  <brief_title>Restylane Defyne for Correction of Chin Retrusion</brief_title>
  <official_title>A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Effectiveness and Safety of Restylane Defyne for Correction of Chin Retrusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, evaluator-blinded, no-treatment controlled study in subjects with Chin&#xD;
      Retrusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GCRS(Galderma Chin Retrusion Scale) at 6 months</measure>
    <time_frame>6 month</time_frame>
    <description>1 point improvement from baseline on the GCRS as measured by the Blinded Evaluator at 6 months (after last treatment in Treatment Group, and after randomization in Control Group)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Chin Retrusion</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection and optional touch-up injection with Restylane Defyne in chin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Defyne</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent to participate in the study.&#xD;
&#xD;
          2. Men or women aged 18 years of age or older of Chinese origin.&#xD;
&#xD;
          3. Subjects seeking augmentation therapy for chin retrusion.&#xD;
&#xD;
          4. GCRS score of 1 or 2 as assessed by the Blinded Evaluator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid gel.&#xD;
&#xD;
          2. Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or&#xD;
             other amide-type anaesthetics.&#xD;
&#xD;
          3. History of severe or multiple allergies, manifested by anaphylaxis.&#xD;
&#xD;
          4. Previous facial surgery, or tissue revitalization treatment with laser or light,&#xD;
             needling, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling or&#xD;
             dermabrasion below the level of the horizontal line from subnasale within 6 months&#xD;
             before treatment.&#xD;
&#xD;
          5. Previous surgery (including aesthetic facial surgical therapy or liposuction),&#xD;
             piercing or tattoo in the area to be treated.&#xD;
&#xD;
          6. Previous tissue augmentation therapy or contouring with any permanent&#xD;
             (non-biodegradable) or semi-permanent filler, autologous fat, lifting threads or&#xD;
             permanent implant below the level of the horizontal line from subnasale.&#xD;
&#xD;
          7. Other condition preventing the subject from entering the study in the Investigator's&#xD;
             opinion, e.g. subjects not likely to avoid other facial cosmetic treatments, subjects&#xD;
             anticipated to be unreliable, unavailable or incapable of understanding the study&#xD;
             assessments or having unrealistic expectations of the treatment result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Q-Med AB</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Chin Retrusion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

